ArticleOncotarget2011

Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience.

Olivier LaRochelle et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.